Longevity Week London: Key quotes and articles

Latest articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Click the globe for translations.

Last week was a big turning point in Longevity: In key centres of academic and scientific endeavour the key players in Longevity aligned.

The three intense days of meetings during Longevity Week London were a key turning point. If you were sceptical about Longevity, or didn’t understand it, the opinions and clarifications delivered by leaders in the sector would have left you in no doubt that the sector is set to address one of the biggest issues and opportunities facing humankind:

Jim Mellon: “If we are going to live to 110-120 the best thing is to invest in the thing that’ll help you get there.”

Dr Aubrey de Grey: “SENS has always been funded through philanthropy to bypass the tyranny of peer review. We don’t work on Longevity, whatever the media may like to tell you. However, we know that our work will increase longevity a lot, I mean really a lot, and yes, we think this is a good side-effect.”

Dmitry Kaminskiy: “Longevity is becoming mainstream among scientists, entrepreneurs, investors, major financial, tech and healthcare corporations, and progressive governments. AI holds unprecedented power to translate research into tangible solutions to extend healthy longevity …”

Dr Nir Barzilai: “Aging is the major risk for heart disease, aging drives diseases. There’s only one thing that we can do and that is target aging which is really the risk for all major diseases.”

Dr Mike West: “Aging is reprogrammable … I think that Washington doesn’t have a clue and I’m sure the public has no idea.”

Richard Siow: AI holds enormous potential to rapidly accelerate the implementation of Longevity R&D … our unique academic-industry focus on preventive and personalised physical, mental and financial health, marking us out from other AI and Ageing centres around the world” said ,

Julia Randell-Khan: “We don’t see long life being a problem, but we have economic systems that are based on life being half as long … People need the answers to questions like, ‘How am I going to afford to retire and how am I going to survive dementia?’ The multi-stage lives that we are now all living means that we need a sense of belonging, sense and worth.” 

Otani Soshi, Japan: “We need to redesign the system. If we allowed citizens to work an extra 10 years between the ages of 65 and 75 we could rebalance the social security system to what it was 15 years ago.”

Jim Mellon: “… we’re the first generation on the planet for whom bioengineering is possible but subsequently stem cells, organ and tissue regeneration and then ultimately gene editing are the things which will keep people alive to 110 or 120. We think those technologies are here today but gene editing will be the reason why the first person to be alive to 150 is living amongst us today.”

These are some of the key articles from last week:

London addresses the 100 year life. Get ready!

Small rooms, big opportunities

First Longevity AI Consortium launched at King’s

Longevity Forum 2019 and the 150 year life

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

Altos Labs lands $3 billion to further cellular rejuvenation programming

Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming. Altos Labs launched today as a new biotechnology company dedicated to unravelling...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

    Subscribe to our newsletter